Indapta Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.indapta.com
Clinical Trials
2
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
- Conditions
- Multiple SclerosisPrimary Progressive Multiple Sclerosis (PPMS)Secondary Progressive Multiple Sclerosis (SPMS)Non-Active Secondary Progressive Multiple SclerosisNon-Active SPMSAutoimmune Diseases of the Nervous SystemNervous System DiseasesAutoimmune DiseasesDemyelinating DiseasesImmune System Diseases
- Interventions
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Indapta Therapeutics, INC.
- Target Recruit Count
- 34
- Registration Number
- NCT06677710
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸AdventHealth Orlando - Adventist Health System/Sunbelt, Inc., Orlando, Florida, United States
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- Conditions
- Relapsed Multiple MyelomaMultiple MyelomaBlood CancerRelapsed Non-Hodgkin LymphomaRefractory Multiple MyelomaNHLRefractory Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Indapta Therapeutics, INC.
- Target Recruit Count
- 128
- Registration Number
- NCT06119685
- Locations
- 🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸Florida Cancer Specialists and Research Institute - Lake Mary Cancer Center, Lake Mary, Florida, United States
🇺🇸Emory University Hospital, Atlanta, Georgia, United States